Full Text View
Tabular View
No Study Results Posted
Related Studies
Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
This study has been completed.
Study NCT00128635   Information provided by National Cancer Institute (NCI)

First Received on August 8, 2005.   Last Updated on April 2, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Central Nervous System Neoplasms
Glioblastoma
Nervous System Neoplasms
More general conditions related to this trial
Astrocytoma
Glioma
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Nervous System Diseases
Neuroectodermal Tumors
Additional drug interventions recognized in this trial
Antibodies
Antibodies, Monoclonal
Immunoglobulins
Iodine
More general drug interventions related to this trial
Anti-Infective Agents
Anti-Infective Agents, Local
Growth Substances
Immunologic Factors
Micronutrients
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Trace Elements
Sponsors listed in this trial
New Approaches to Brain Tumor Therapy Consortium
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services